Virtu Financial LLC Takes Position in CRISPR Therapeutics AG $CRSP

Virtu Financial LLC bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 16,444 shares of the company’s stock, valued at approximately $862,000.

A number of other institutional investors have also added to or reduced their stakes in CRSP. Mcguire Capital Advisors Inc. acquired a new stake in CRISPR Therapeutics in the fourth quarter valued at approximately $25,000. Ramirez Asset Management Inc. bought a new stake in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $26,000. Rothschild Investment LLC raised its position in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock worth $29,000 after purchasing an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its position in shares of CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after purchasing an additional 382 shares during the period. Finally, Optiver Holding B.V. lifted its holdings in shares of CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after purchasing an additional 210 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,786 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the transaction, the insider directly owned 19,357 shares of the company’s stock, valued at $1,076,636.34. This trade represents a 16.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $54.09 on Monday. The firm has a market capitalization of $5.22 billion, a P/E ratio of -8.70 and a beta of 1.74. The business has a fifty day simple moving average of $52.73 and a 200 day simple moving average of $53.10. CRISPR Therapeutics AG has a 12 month low of $43.23 and a 12 month high of $78.48. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. The firm had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%. On average, analysts predict that CRISPR Therapeutics AG will post -4.89 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on CRSP shares. Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Monday, April 20th. Wall Street Zen lowered shares of CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. Sanford C. Bernstein lifted their price objective on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Finally, Truist Financial raised shares of CRISPR Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $67.78.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.